Kim Hee-Hoon, Shim Young-Ri, Choi Sung Eun, Falana Tolulope Esther, Yoo Jae-Kwang, Ahn So-Hee, Park Minhye, Seo Hyangmi, Choi Chulhee, Jeong Won-Il
Laboratory of Liver Research, Graduate School of Medical Science and Engineering, KAIST, Daejeon 34141, Republic of Korea.
ILIAS Biologics Inc., Daejeon 34014, Republic of Korea.
Pharmaceutics. 2023 Feb 14;15(2):636. doi: 10.3390/pharmaceutics15020636.
Activation of Kupffer cells (KCs) by gut-derived lipopolysaccharide (LPS) instigates nuclear factor-κB (NF-κB)-mediated inflammatory responses in alcohol-associated liver diseases (ALD). Here, we utilized a novel optogenetically engineered exosome technology called 'exosomes for protein loading via optically reversible protein-protein interactions (EXPLOR)' to efficiently deliver the super-repressor IκB-loaded exosomes (Exo-srIκB) to the liver and examined its therapeutic potential in acute-on-chronic alcohol-associated liver injury. We detected enhanced uptake of DiI-labeled Exo-srIκB by LPS-treated inflammatory KCs, which suppressed LPS-induced inflammatory gene expression levels. In animal experiments, a single intravenous injection of Exo-srIκB prior to alcohol binge drinking significantly attenuated alcohol-associated hepatic steatosis and infiltration of neutrophils and macrophages but not a liver injury. Notably, three consecutive days of Exo-srIκB injection remarkably reduced alcohol-associated liver injury, steatosis, apoptosis of hepatocytes, fibrosis-related gene expression levels in hepatic stellate cells, infiltration of neutrophils and macrophages, and inflammatory gene expression levels in hepatocytes and KCs. In particular, the above effects occurred with inhibition of nuclear translocation of NF-κB in liver tissues, and these beneficial effects of Exo-srIκB on ALD were shown regardless of doses. Our results suggest an exosome-based modulation of NF-κB activity in KCs by Exo-srIκB as a novel and efficient therapeutic approach in ALD.
肠道来源的脂多糖(LPS)激活库普弗细胞(KC)会引发酒精性肝病(ALD)中核因子κB(NF-κB)介导的炎症反应。在此,我们利用一种名为“通过光学可逆蛋白质-蛋白质相互作用进行蛋白质加载的外泌体(EXPLOR)”的新型光遗传学工程外泌体技术,将负载超抑制因子IκB的外泌体(Exo-srIκB)有效递送至肝脏,并研究其在急性-on-慢性酒精性肝损伤中的治疗潜力。我们检测到LPS处理的炎性KC对DiI标记的Exo-srIκB摄取增强,这抑制了LPS诱导的炎症基因表达水平。在动物实验中,在暴饮酒精之前单次静脉注射Exo-srIκB可显著减轻酒精相关的肝脂肪变性以及中性粒细胞和巨噬细胞浸润,但对肝损伤无作用。值得注意的是,连续三天注射Exo-srIκB可显著降低酒精相关的肝损伤、脂肪变性、肝细胞凋亡、肝星状细胞中纤维化相关基因表达水平、中性粒细胞和巨噬细胞浸润以及肝细胞和KC中的炎症基因表达水平。特别是,上述效应伴随着肝组织中NF-κB核转位的抑制而出现,并且Exo-srIκB对ALD的这些有益作用与剂量无关。我们的结果表明,Exo-srIκB对KC中NF-κB活性进行基于外泌体的调节是ALD一种新型且有效的治疗方法。